OpenEvidence: How AI is Transforming Clinical Research

Physicians treating patients with complex symptoms face a familiar challenge: sifting through thousands of medical studies to find relevant evidence whilst patients wait. This scenario occurs millions of times daily across healthcare systems worldwide, where clinicians must balance thoroughness with speed in life-or-death situations.

The challenge has intensified as medical knowledge continues to expand. The volume of peer-reviewed medical research published annually doubles every five years, with over 1.5 million new papers added to PubMed each year. Healthcare systems confront a looming staffing crisis, with the US alone facing a projected physician shortfall of nearly 100,000 by 2030.

OpenEvidence has closed a $210m Series B funding round at a $3.5bn valuation, with Google Ventures and Kleiner Perkins co-leading the investment. The Cambridge-based medical AI company has raised more than $300m since its founding and now serves over 40% of physicians in the United States who log in daily to make clinical decisions.

The platform operates across more than 10,000 hospitals and medical centres nationwide, with over 65,000 new verified US clinician registrations each month. In July 2024, OpenEvidence supported approximately 358,000 logged-in physician consultations in one month. One year later, the platform now handles that volume each workday.

OpenEvidence DeepConsult targets complex medical research

OpenEvidence has announced the wide release of OpenEvidence DeepConsult, described as the first AI agent purpose-built for physicians. The system uses reasoning models to autonomously analyse and cross-reference hundreds of peer-reviewed medical studies in parallel, providing comprehensive research reports that would otherwise require months of human effort.

Each DeepConsult run requires over 100 times the compute and cost of a standard OpenEvidence search. While some foundation model companies have publicly speculated about charging tens of thousands of dollars per month for PhD-level agents still under development, OpenEvidence offers DeepConsult free to all verified US clinicians.

"At a time when US healthcare faces the dual challenges of clinician burnout and a projected physician shortfall of nearly 100,000 by 2030, the question of AI's role in bridging the gap is paramount," says Daniel Nadler, founder of OpenEvidence. "When physicians' lives are hard, patients' lives are harder."

Google Ventures backs OpenEvidence clinical adoption

Sangeen Zeb, General Partner at Google Ventures, highlighted the founder's track record and the platform's clinical adoption. "Daniel Nadler is a magnet for talent, attracting top AI researchers and a world-class medical advisory board," he says. "As a firm with a life sciences team largely composed of physicians and scientists, we deeply understand the challenges clinicians face with traditional tools. Physicians are drowning in information but starving for timely insights. OpenEvidence changes that equation, bringing clinicians into the modern era."

John Doerr, Chairman of Kleiner Perkins who co-led Google's original Series A and has served on its board since 1999, expressed confidence in the platform's potential. "It's hard to imagine a better use for AI than OpenEvidence," says Doerr. "Daniel Nadler and his world-class team are building what I believe will become an AI-era treasure, a life-saving resource for doctors, patients and their families."

Kleiner Perkins highlights OpenEvidence physician adoption rates

OpenEvidence was founded by Daniel Nadler and Zachary Ziegler. Daniel previously founded Kensho, which S&P Global acquired for $700 million in 2018. Google Ventures was the first major investor in Kensho, funding the company while Daniel was completing his PhD at Harvard University. In 2025, he was named to the TIME100 Health list of the 100 Most Influential People in global health.

Mamoon Hamid, Managing Partner at Kleiner Perkins, noted the platform's adoption amongst physicians. "It's exceptionally rare to see a product reach this level of adoption – let alone among physicians, who are notoriously hard to win over and exacting in what they trust – and the fact that 40% of all physicians in the United States log in daily to OpenEvidence's software is a staggering signal of both trust and utility," says Hamid. "OpenEvidence is not just building a company, they're setting a new global standard for how evidence-based medical decisions are made."